Long-acting injectable cabotegravir for the prevention of HIV infection

Meredith E. Clement(Louisiana State University Health Sciences Center New Orleans), Raphael J. Landovitz(APLA Health), Ryan Kofron(APLA Health)
Current Opinion in HIV and AIDS
October 23, 2019
10.1097/coh.0000000000000597
Cited by 106

Related Papers

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
|New England Journal of Medicine|2021|847
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
|JAMA|2016|655
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
|JAMA|2018|557
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
|JAMA|2022|547
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults
|JAMA|2020|466